The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. ("Artisan") and Tulex Pharmaceuticals ("Tulex" ...
BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it ...
Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome ...
Since 2013, when the DSM-5 collapsed five autism subtypes into the single diagnosis of "autism spectrum disorder (ASD)," we've treated autism like a monolith. Maybe that made sense when our tools were ...
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Artisan Therapeutics, Inc. (“Artisan”) and Tulex Pharmaceuticals (“Tulex”) today announced encouraging Phase 2a clinical results highlighting the potential ...
PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback